Lymphoma drug duvelisib tested after transplant – trial ends early
NCT ID NCT04331119
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full results are not available, but the approach aimed to improve progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Duvelisib (Copiktra)
- What this could lead to
- If successful, this could point toward a way to keep T-cell lymphoma from returning after a stem cell transplant.
- What could go wrong
- This was a small, early-phase trial that was terminated, so results are limited. Duvelisib can cause serious side effects like infections and liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
- New study aims to decode PTCL by genetic subtype
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New pill shows promise for rare blood cancer in Late-Stage trial